Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Congratulatory remarks

Si Hyun Bae

Clin Mol Hepatol. 2023;29(Suppl):S1-S1. Published online February 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0027

Preface

Yoon Jun Kim

Clin Mol Hepatol. 2023;29(Suppl):S2-S2. Published online February 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0011

Preface

Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S3-S3. Published online February 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0014

Special thanks

Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S4-S4. Published online February 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0010

Reviews

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

Web of Science 22 Crossref 24

DOI: https://doi.org/10.3350/cmh.2022.0424

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

Web of Science 36 Crossref 51

DOI: https://doi.org/10.3350/cmh.2022.0367

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

Web of Science 54 Crossref 76

DOI: https://doi.org/10.3350/cmh.2022.0365

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

Web of Science 13 Crossref 13

DOI: https://doi.org/10.3350/cmh.2022.0351

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

Web of Science 10 Crossref 13

DOI: https://doi.org/10.3350/cmh.2022.0350

Interaction between sarcopenia and nonalcoholic fatty liver disease

Sae Kyung Joo, Won Kim

Clin Mol Hepatol. 2023;29(Suppl):S68-S78. Published online December 5, 2022

Web of Science 16 Crossref 17

DOI: https://doi.org/10.3350/cmh.2022.0358

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

Web of Science 15 Crossref 18

DOI: https://doi.org/10.3350/cmh.2022.0398

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

Web of Science 7 Crossref 9

DOI: https://doi.org/10.3350/cmh.2022.0442

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

Web of Science 12 Crossref 14

DOI: https://doi.org/10.3350/cmh.2022.0336

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

Web of Science 5 Crossref 6

DOI: https://doi.org/10.3350/cmh.2022.0357

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

Web of Science 13 Crossref 11

DOI: https://doi.org/10.3350/cmh.2022.0436

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

Web of Science 7 Crossref 8

DOI: https://doi.org/10.3350/cmh.2022.0362

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

Web of Science 12 Crossref 13

DOI: https://doi.org/10.3350/cmh.2022.0348

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong

Clin Mol Hepatol. 2023;29(Suppl):S171-S183. Published online December 12, 2022

Web of Science 5 Crossref 5

DOI: https://doi.org/10.3350/cmh.2022.0426

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

Web of Science 8 Crossref 8

DOI: https://doi.org/10.3350/cmh.2022.0318

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

Web of Science 8 Crossref 8

DOI: https://doi.org/10.3350/cmh.2022.0431

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Karim Seif El Dahan, Darine Daher, Amit G. Singal

Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online September 14, 2022

Web of Science 4 Crossref 6

DOI: https://doi.org/10.3350/cmh.2022.0247

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2022.0360

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease

Georg Semmler, Christian Datz, Michael Trauner

Clin Mol Hepatol. 2023;29(Suppl):S244-S260. Published online December 14, 2022

Web of Science 6 Crossref 7

DOI: https://doi.org/10.3350/cmh.2022.0364

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2023;29(Suppl):S261-S267. Published online December 22, 2022

Web of Science 4 Crossref 5

DOI: https://doi.org/10.3350/cmh.2022.0393

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

Web of Science 8 Crossref 10

DOI: https://doi.org/10.3350/cmh.2022.0437

Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management

Anja Geerts, Sander Lefere

Clin Mol Hepatol. 2023;29(Suppl):S276-S285. Published online December 22, 2022

Web of Science 4 Crossref 4

DOI: https://doi.org/10.3350/cmh.2022.0373

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

Web of Science 9 Crossref 9

DOI: https://doi.org/10.3350/cmh.2022.0392

Non-alcoholic fatty liver disease: the pathologist’s perspective

Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim

Clin Mol Hepatol. 2023;29(Suppl):S302-S318. Published online November 15, 2022

Web of Science 6 Crossref 6

DOI: https://doi.org/10.3350/cmh.2022.0329

Original Article

The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review

George Chen, Bubu Banini, Albert Do, Joseph K. Lim

Clin Mol Hepatol. 2023;29(Suppl):S319-S332. Published online December 14, 2022

Web of Science 3 Crossref 4

DOI: https://doi.org/10.3350/cmh.2022.0366

Viewed By 5176	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5034	MAFLD: How is it different from NAFLD?
Viewed By 4985	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3674	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3628	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Previous issues